Moderna $MRNA Surges 133%: mRNA Cancer Vaccine Finally Works

$MRNA is having the kind of day that makes short sellers rethink their career choices. Moderna surged as much as 133%, hitting approximately $107 per share (up over $43), after reporting that its personalized mRNA-based melanoma vaccine, developed alongside $MRK, succeeded in a Phase 3 trial preventing the cancer from returning or spreading in high-risk patients who had already undergone surgery.

The treatment pairs Moderna's individualized mRNA therapy with Merck's blockbuster immunotherapy Keytruda (pembrolizumab), and the results are genuinely meaningful, not just a vibes-based biotech pump. Merck itself rose roughly 9% on the same news, and smaller mRNA-adjacent name Arcturus Biotech also caught a sympathy bid. When the partner pops 9% on your good news, the market is telling you something real.

The bull case here is straightforward: this validates the entire mRNA platform as a vehicle for personalized oncology, not just infectious disease vaccines. Moderna's revenue run rate has been struggling post-COVID, and this result opens a genuinely enormous addressable market. Analysts at Bloomberg noted that significant short covering is likely inflating the intraday move, but even after you strip out the squeezed shorts, the fundamental shift in Moderna's pipeline credibility is hard to dismiss.

The bear case, which you should actually read before buying at the open: the stock was trading around $50 before this news, meaning the market had already priced in a company whose main product cycle had faded. Scaling personalized mRNA vaccines is brutally expensive, a custom sequence has to be designed and manufactured for each individual patient. Margins will not look anything like Keytruda's. And Merck gets a meaningful cut of any commercial revenue, since Keytruda is the immunotherapy backbone of the entire regimen.

Also worth watching: $MRNA reaching a commercial agreement with payers for individualized cancer therapy is a regulatory and reimbursement obstacle course that could take years. The trial success is real. The path from Phase 3 to pharmacy shelf is where dreams go to get rescheduled.

For now though, the mRNA comeback tour is officially back on the calendar, and anyone who was calling this technology a pandemic-era fluke just got a very expensive lesson in not writing off platform biotech.